The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer

Archives of Gynecology and Obstetrics

Volumn 284, Issue 1, 2011, Pages 183-190

  Koh, Stephen C L ^a   Razvi, K ^b   Chan, Y H ^a   Narasimhan, K ^a   Ilancheran, A ^a   Low, J J ^a   Choolani, M ^a   Sahil, F ^c   Lutan, D ^c   Siddik, D ^c   Suwiyoga, K ^d   Budiana, G ^d   Pradjitmo, H ^e   Saleh, A Z ^f   Aziz, M F ^g   Winarto, H ^g   Thanh, P V ^h   Hoan, N K H ^h   Ravichandran, I ⁱ   Dominic, N ⁱ  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SUMATERA UTARA   (Indonesia)

^d UDAYANA UNIVERSITY   (Indonesia)

^e GADJAH MADA UNIVERSITY   (Indonesia)

^f SRIWIJAYA UNIVERSITY   (Indonesia)

^g CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^h Tu du Hospital   (Viet Nam)

ⁱ Sultanah Aminah Hosiptal ^*  (Malaysia)

Author keywords

Age; Hemostatic markers; KLK10; KLK6; Ovarian cancer

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; D DIMER; FIBRINOGEN; KALLIKREIN; KALLIKREIN 10; KALLIKREIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN ANTIBODY; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VON WILLEBRAND FACTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; CYST; FEMALE; HEMOSTASIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; UPREGULATION;

ADULT; AGE FACTORS; CA-125 ANTIGEN; FEMALE; HEMOSTASIS; HUMANS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN CYSTS; OVARIAN NEOPLASMS; OVARY; RETROSPECTIVE STUDIES; SINGAPORE;

EID: 79958793918     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-010-1605-z     Document Type: Article

References (35)

1. Schink JC (1999) Current initial therapy of stage III and IV ovarian cancer; challenges for managed care. Semin Oncol 26:2-7
2. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519-2529
3. Bick RL (1992) Disseminated intravascular coagulation. Lab Med 23:161
4. Constantini V, Zacharaski L-R (1993) Fibrin and cancer. Thromb Haemost 69:406-414
5. Miyauchi S, Moroyama S, Moroyama T, Kyoizumi S, Asakawa J-I, Okamoto T, Takada K (1988) Malignant tumour cell lines produce intereleukin-1 like factor. In Vitro Cell Dev Biol 24:753-758
6. Kakkar AK, Chinswangwatanakul V, Tebutt S, Williamson RC (1995) Extrinsic pathway activation in cancer with high factor VIIa and tissue factor. Lancet 6:885-888
7. Koh CL Stephen, Tham K-F, Razvi-K, Oei PL, Lim FK, Roy AC, Parasad RNV (2001) Haemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could D-dimer and antithrombin III levels be included as prognostic markers for survival outcome? Clin Appl Thromb Hemost 7(2):141-148
8. van Wersch JWJ, Peters C, Ubachs JMH (1995) Haemostasis in benign and malignant gynaecological tumors: a pilot study. Eur J Clin Chem Clin Biochem 33:225-229
9. Von Tempelhof G-F, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L (1997) Blood coagulation and thrombosis in patients with ovarian cancer. Thromb Haemost 77:456-461 (Pubitemid 27121008)
10. Borgfeldt C, Bendahl P-O, Ferno M, Casslen B (2003) High preoperative plasma concentration of tissue plasminogen activator (tPA) is an independent marker for shorter overall survival in patients with ovarian cancer. Gynecol Oncol 91:112-117 (Pubitemid 37203406)
11. Riisbro R, Stephens RW, Brunner N, Christensen IJ, Nielsen HJ, Heilmann L, von Tempelhof G-F (2001) Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Gynecol Oncol 82:523-531 (Pubitemid 32826454)
12. Beer JH, Haeberti A, Vogt A, Woodtli K, Henkel E, Furrer T, Fey MF (2002) Coagulation markers predict survival in cancer patients. Thromb Haemost 88:745-749 (Pubitemid 35345330)
13. Stephen KohCL, Khalil R, Lim FK, Ilancheran A, Choolani M (2006) The association between fibrinogen, von Willebrand Factor, antithrombin III and D-dimer levels and survival outcome by 36 months from ovarian cancer. Clin Appl Thromb Hemost 12:3-8 (Pubitemid 43221565)
14. Duffy MJ (1995) Proteases as prognostic markers in cancer. Clin Cancer Res 2:613-618
15. Diamandis EP, Yousef GM (2002) Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem 48:1198-1205 (Pubitemid 34809825)
16. Diamandis EP, Scorilas A, Fracchioli S et al (2003) Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 21(6):1035-1043 (Pubitemid 46594132)
17. Obiezu CV, Diamandis EP (2005) Human tissue kallikrein gene family: applications in cancer. Cancer Lett 224(1):1-22 (Pubitemid 40720363)
18. Borgono CA, Kishi T, Scorilas A, Harbeck N, Dorn J, Schmafeldt B, Schmitt M, Diamandis EP (2006) Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Clin Cancer Res 12:1487-1493
19. Yousef GM, Diamandis EP (2001) The new human tissue kallikrein gene family: structure, function and association to disease. Endocr Rev 22:184-204 (Pubitemid 32458158)
20. Diamandis EP, Okui A, Mitsui S, Luo L-Y, Soosaipillai A, Grass L, Nakamura T, Howarth JC, Yamaguchi N (2002) Human kallikrein 11: a new biomarker of prostate and ovarian cancer. Cancer Res 62:295-300 (Pubitemid 34074018)
21. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB (1998) CA-125, the past and the future. Int J Biol Markers 13:179-187
22. Mills GB, Bast RC, Srivastava S (2001) Future for ovarian cancer screening, novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst (Bethesda) 93:1437-1439 (Pubitemid 32982666)
23. Koh SCL, Yuen R, Viegas OAC, Chua SE, Ng BL, Sen DK, Ratnam SS (1989) A plasmin generation method for the determination of t-PA activity in blood. Immunol Cell Biol 67:197-203 (Pubitemid 20034797)
24. Koh SCL, Yuen R, Viegas OAC, Chua SE, Ng BL, Sen DK, Ratnam SS (1989) Plasma tissue plasminogen activator inhibitor (t-PAI) activity in normal subjects. Med Sci Res 17:135-136
25. Gaducci A, Baicchhi U, Marrai R et al (1996) Preoperative evaluation of D-dimer and CA-125 levels to differentiate benign from malignant ovarian masses. Gynecol Oncol 60:197-202 (Pubitemid 26058762)
26. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K, Brunner N (1999) Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 91:869-874 (Pubitemid 29252303)
27. Fernebro E, Madsen RR, Ferno M, Brunner N, Bendahl N, Bendahl P, Christensen IJ, Johnson A, Nilbert M (2001) Prognostic importance of the soluble plasminogen activator receptor, suPAR in plasma from rectal cancer patients. Eur J Cancer 37:486-491 (Pubitemid 32232113)
28. Koh CLS, Sahil F, Lutan D, Siddik D, Suwiyoga K, Budiana G, Pradjatmo H, Saleh AZ, Aziz MF, Winarto H, Narasimhan K, Ilancheran A, Razvi K, Choolani M (2009) Systemic ovarian cancer biomarkers in Indonesian women with ovarian tumours Systemic ovarian cancer biomarkers in Indonesian women with ovarian tumours. Abstract 38, The 7th Singapore international congress of O&G, 26-29 August 2009, Singapore
29. Kramer BS, Gohagar J, Prorok PC, Smart C (1993). A national cancer institute sponsored screening trial for prostatic, lung, colorectal and ovarian cancers. Cancer Suppl 71:589-593 (Pubitemid 23021255)
30. Bjorge T, Engeland A, Hansen S, Trope CG (1998) Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993. Int J Cancer 75:663-670 (Pubitemid 28145810)
31. Luo L-Y, Katsaros D, Scorilas A, Francchioli S, Bellino R, van Gramberen M, de Bruijn H, Henrik A, Stenman U-H, Massobrio M, van de Zee AGJ, Vergote I, Diamandis EP (2003) The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 63:807-811 (Pubitemid 36231980)
32. Razvi K, Koh, SCL, Loganath A, Narasimhan K, Ilancheran A, Choolani M (2005) Human tissue kallikreins, hK6, hK10 as novel biomarkers for epithelial ovarian cancer. J Thromb Haemost 5(Suppl 2) (abstract)
33. Ni X, Zhang W, Huang K-C, Wang Y, Ng S-K, Mok SC, Berkowitz RS, Ng S-W (2004) Characterization of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer 91:725-731 (Pubitemid 39141632)
34. Luo L-Y, Bunting P, Scorilas A, Diamandis EP (2001) Human kallikrein 10: a novel tumor marker for ovarian carcinoma? Clin Chim Acta 306:111-118
35. Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RC, Gershenson DM, Schmandt R (2003) Over expression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 90:44-50 (Pubitemid 37338074)